Brivaracetam Film-coated tablet + Brivaracetam oral solution

Phase 3Recruiting
0 watching 0 views this week๐Ÿ“ˆ Rising
74
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Childhood Absence Epilepsy

Conditions

Childhood Absence Epilepsy, Juvenile Absence Epilepsy

Trial Timeline

Jul 10, 2024 โ†’ Mar 1, 2030

About Brivaracetam Film-coated tablet + Brivaracetam oral solution

Brivaracetam Film-coated tablet + Brivaracetam oral solution is a phase 3 stage product being developed by UCB for Childhood Absence Epilepsy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06315322. Target conditions include Childhood Absence Epilepsy, Juvenile Absence Epilepsy.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT06315322Phase 3Recruiting
NCT05109234Phase 3Completed